| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 1/20-1/50 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ERLEC2; Os9;;OS 9 |
| WB Predicted band size | Calculated MW: 76 kDa ; Observed MW: 83,97 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human OS 9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于OS9抗体的模拟参考文献示例(注：文献为虚构，仅供示例用途，实际引用请通过学术数据库查询)：
---
1. **文献名称**: *OS9 interacts with HIF-1α and regulates its stability in hypoxic tumor cells*
**作者**: Zhang L, et al.
**摘要**: 研究揭示了OS9蛋白通过直接结合缺氧诱导因子HIF-1α，促进其蛋白酶体降解，从而抑制肿瘤细胞在低氧环境中的适应能力。实验使用OS9抗体进行免疫共沉淀(Co-IP)，证实了二者的相互作用。
---
2. **文献名称**: *OS9 as a biomarker for endoplasmic reticulum stress in neurodegenerative diseases*
**作者**: Tanaka K, et al.
**摘要**: 本文通过OS9抗体检测阿尔茨海默病模型小鼠脑组织中的OS9表达，发现其与内质网应激标志物GRP78共定位，提示OS9可作为神经退行性疾病中ER应激的潜在生物标志物。
---
3. **文献名称**: *Targeting OS9 enhances chemotherapy sensitivity in colorectal cancer*
**作者**: Chen H, et al.
**摘要**: 研究利用OS9抗体进行免疫组化分析，发现高表达OS9的结直肠癌患者对奥沙利铂化疗耐药。机制研究表明，OS9通过调控EGFR通路影响DNA损伤修复，抑制OS9可增强化疗效果。
---
4. **文献名称**: *OS9-mediated quality control of glycoproteins in the ERAD pathway*
**作者**: Wang Y, et al.
**摘要**: 通过OS9抗体和基因敲除实验，证实OS9在内质网相关降解(ERAD)中识别错误折叠的糖蛋白，并与Sel1L-HRD1复合物协同促进底物泛素化及降解。
---
如需真实文献，建议通过PubMed、Google Scholar等平台检索关键词(如“OS9 antibody”、“OS9 protein function”)。
OS9 (Osteosarcoma amplified 9) is a glycoprotein encoded by the *OS9* gene, initially identified due to its amplification in osteosarcoma. It is a key component of the endoplasmic reticulum (ER)-associated degradation (ERAD) pathway, which monitors protein quality control. OS9 acts as an ERAD adaptor that recognizes misfolded or unassembled glycoproteins in the ER lumen, tagging them for retrotranslocation to the cytoplasm and subsequent proteasomal degradation. This process involves interactions with ER-resident lectins (e.g., SEL1L, HRD1) and components of the ubiquitin-proteasome system. Dysregulation of OS9 or ERAD is implicated in diseases like cancer, neurodegeneration, and metabolic disorders.
OS9 antibodies are research tools used to detect and study OS9 expression, localization, and function. They are critical for investigating ER stress, protein homeostasis, and disease mechanisms. Commercially available OS9 antibodies are typically monoclonal or polyclonal, validated for applications like Western blotting, immunofluorescence, and immunoprecipitation. Researchers utilize these antibodies to explore OS9’s role in tumor progression (e.g., osteosarcoma, glioblastoma), its interaction with hypoxia-inducible factors (HIFs) in hypoxic microenvironments, and its contribution to neurodegenerative proteinopathies. Proper validation of antibody specificity using knockout controls is essential due to potential cross-reactivity with homologous proteins like OS9B.
×
